Renaming Polycystic Ovarian Syndrome to Polyendocrine Metabolic Ovarian Syndrome: A Global Effort to Reframe a Complex Condition

A Lancet paper published Tuesday officially replaces “polycystic ovarian syndrome” (PCOS) with “polyendocrine metabolic ovarian syndrome” (PMOS). The change is led by Dr. Helena Teede, an endocrinologist at Monash University, and reflects a 14-year, worldwide collaboration among 56 patient and professional organizations.

CNN

Originally described as a reproductive disorder characterized by ovarian cysts and irregular periods, PCOS was later linked in the 1980s to insulin resistance. Subsequent research identified broader metabolic disturbances, including heightened risk of type 2 diabetes, cardiovascular disease, liver disease, sleep apnea, depression, anxiety, and body-dysmorphia.

CNN

Key figures include Dr. Alla Vash-Margita (Yale University), Dr. Andrea Dunaif (Icahn School of Medicine at Mount Sinai), Rachel Morman, chair of Verity PCOS UK, and Dr. Christina Boots (Northwestern University). Their institutions and the 56 partnering groups provided the multidisciplinary input that shaped the new terminology.

CNN

The World Health Organization estimates that 10 %–13 % of women of reproductive age worldwide have the syndrome, yet roughly 70 % remain unaware of their diagnosis. The opaque name is cited as a major factor in missed detection and delayed treatment.

CNN

“Polyendocrine” signals the condition’s hormonal dysregulation, while “metabolic” highlights its systemic impact beyond the ovaries. Advocates argue the former label fostered stigma by suggesting visible cysts, obscuring the condition’s mental-health and metabolic dimensions. The revised name aims to prompt broader clinical awareness and more comprehensive insurance coverage.

CNN

Dr. Teede emphasized that the new terminology “gives importance to the wide range of impacts” and should guide multidisciplinary care. Dr. Vash-Margita noted that the prior name “missed the big picture” and perpetuated myths. Rachel Morman described the shift as a way to “reframe the conversation” and demand serious attention. Dr. Boots linked the renaming to potential increases in research funding, stating that “women’s health is notoriously underfunded.”

CNN

Dr. Dunaif cautioned that PMOS still does not capture emerging nuances, such as metabolic manifestations in individuals without ovaries. She suggested sub-typing the condition into primarily reproductive versus primarily metabolic phenotypes to improve diagnostic precision.

CNN

• “By calling this condition polycystic ovary, we’re missing the big picture,” — Dr. Alla Vash-Margita, Yale University

CNN

• “The body has to produce more insulin, and if the body can’t kind of keep up with the needs, then diabetes can develop,” — Dr. Andrea Dunaif, Icahn School of Medicine

CNN

• “This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is,” — Rachel Morman, Verity PCOS UK

CNN

• “Women’s health is notoriously underfunded,” — Dr. Christina Boots, Northwestern University

CNN

• “Seeing these patients as people, and doing our best to give them care with empathy and individualizing their care, I just think is so important.” — Dr. Christina Boots, Northwestern University

CNN

Experts call for integrated care pathways that unite endocrinology, gynecology, psychiatry, nutrition, and primary care. Lifestyle modification and weight loss remain first-line interventions; GLP-1 agonists show promise despite limited trial data in women with PMOS. Ongoing research aims to refine diagnostic criteria, evaluate subtype-specific therapies, and secure broader insurance reimbursement.

CNN